Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score–matched analysis

Takanori Miyoshi1 · Toshinobu Hayashi2· Miyuki Uoi3 · Fuyuki Omura1 · Kyouichi Tsumagari4 · Sachi Maesaki5 · Chiaki Yokota6 · Takafumi Nakano2 · Takashi Egawa2

Received: 16 September 2021 / Accepted: 30 December 2021 / Published online: 5 January 2022
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abstract
Purpose The protective effect of magnesium (Mg) supplementation against cisplatin (CDDP)-induced nephrotoxicity has been widely described; however, the optimal dose of Mg supplementation is unclear. The aim of this study was to investigate whether 20 mEq of Mg supplementation is more effective than 8 mEq Mg in preventing CDDP-induced nephrotoxicity, as well as the associated risk factors, in cancer patients treated with CDDP-based chemotherapy.

Methods Pooled data of 272 patients receiving 20 mEq or 8 mEq Mg supplementation to CDDP-based chemotherapy from a multicenter, retrospective, observational study were compared using propensity score matching. Separate multivariate logistic regression analyses were used to identify the risk factors for renal failure induced by each treatment dose.

Results There was no significant difference in the incidence of nephrotoxicity between the 8 mEq and 20 mEq groups ($P = 0.926$). There was also no significant difference in the severity of nephrotoxicity, elevated serum creatinine levels, and decreased estimated creatinine clearance levels between the two groups. Cardiac disease and albumin levels were identified as independent risk factors for CDDP-induced nephrotoxicity.

Conclusion We did not find an advantage of 20 mEq over 8 mEq Mg supplementation in terms of a preventive effect against CDDP-induced nephrotoxicity. The optimal dose of Mg supplementation for the prevention of CDDP-induced nephrotoxicity remains unknown, and further studies are warranted.

Keywords Cisplatin · Nephrotoxicity · Renal failure · Magnesium supplementation

Introduction
Cisplatin (cis-dichlorodiamineplatinum II, CDDP) is one of the most widely used anticancer agents, representing a key drug in the treatment of several solid cancers [1]. However, CDDP-induced nephrotoxicity is a major dose-limiting factor that can influence the therapeutic efficacy [2, 3]. Renal dysfunction often causes a delay in or discontinuation of chemotherapy; therefore, it is important to minimize the incidence and severity of nephrotoxicity. Previous studies have shown that CDDP-induced nephrotoxicity can be prevented or reduced by lowering the concentration of CDDP.
and shortening the duration of CDDP exposure to the proximal tubules [4]. Several other strategies have been reported to prevent CDDP-induced nephrotoxicity, including high-volume hydration with at least 2 L of isotonic saline, forced diuresis with furosemide or mannitol, dose fractionation, and slower infusion [5–8].

Hypomagnesemia is another well-known adverse effect in patients receiving CDDP-based chemotherapy, which has been reported to occur in approximately 90% of patients receiving CDDP [9]. CDDP-induced hypomagnesemia and hypocalcemia have been suggested to be caused by damage to the renal tubular cells and calcium/magnesium (Mg)-sensitive receptors [9, 10]. Hypomagnesemia has also been recognized as a risk factor for impaired recovery of renal function in patients with severe acute kidney injury (AKI) [11]. Previous studies have shown that Mg supplementation during CDDP-based chemotherapy correlated with the prevention of CDDP-induced nephrotoxicity [12–14]. However, these studies have used varying doses of Mg supplementation, demonstrating that 8 mEq [15–17], 20 mEq [18, 19], and 40 mEq [12] of intravenous Mg supplementation all had preventive effects against CDDP-induced nephrotoxicity. Mg supplementation is most frequently administered at a dose of 8 mEq according to the National Comprehensive Cancer Network (NCCN) order template and/or the results of studies in Japan [15–17]. However, Hase et al. [19] reported that 20 mEq of Mg supplementation with a short hydration regimen was safe and feasible for patients with lung cancer receiving CDDP-based chemotherapy. Although the protective effect of Mg supplementation has been described in several studies, the optimal dose remains unclear. Mg supplementation should be kept to a necessity minimum, as there is concern that renal dysfunction may lead to hypermagnesemia. In our previous study reporting the risk factors for CDDP-induced nephrotoxicity [20], cardiac disease, hypoalbuminemia, non-Mg supplementation, hypertension, and high-dose CDDP were extracted as risk factors.

Therefore, in this study, we investigated whether 20 mEq of Mg supplementation is more effective than 8 mEq of Mg in preventing CDDP-induced nephrotoxicity, as well as the associated risk factors in cancer patients treated with CDDP-based chemotherapy, based on a pooled dataset of our previous study [20].

Methods

Setting and patients

The study design, including patient enrollment, data collection, and treatment, has been described previously [20]. In brief, this multicenter, retrospective, observational study was conducted from spring 2014 to September 2016 in five hospitals affiliated with the National Hospital Organization in Kyushu, Japan. We analyzed the pooled data of 345 patients in this study [20]. This study was approved by the Institutional Review Board of each hospital. All patients were treated in accordance with the principles outlined in the Declaration of Helsinki. Accumulated patient data were used after allowing patients to refuse to participate using an opt-out form. The requirement for informed consent was waived because of the retrospective nature of the study. Patients with solid cancer, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, and those who had received Mg supplementation to CDDP-based therapy were eligible for inclusion in the present study. The exclusion criteria were prior CDDP-based chemotherapy or creatinine clearance (CLcr) < 60 mL/min immediately prior to CDDP administration.

Data collection

All data were collected from the medical records at each hospital. Information on sex; age; ECOG PS; cancer stage; primary cancer site; comorbidities (cardiac disease, diabetes mellitus, hypertension); and hematological, biochemical, and chemotherapeutic regimens (i.e., co-administered anticancer drugs, CDDP dosage, hydration volume, Mg supplementation, diuretics) was collected. We defined 2.5-L hydration within approximately 4.5 h as short hydration [13] and other hydration methods (> 2.5 L) as the conventional high-volume hydration. In this study, all patients received conventional high-volume hydration. Cardiac disease was defined as a history of angina, myocardial infarction, atrial fibrillation, arrhythmia, or valvular disease. The medical records of all patients were retrospectively reviewed to confirm the diagnosis of diabetes and high blood pressure.

To evaluate nephrotoxicity, the increase in serum creatinine (SCr) was calculated using the maximum value based on an enzymatic method within 2 weeks of CDDP-based chemotherapy. For most patients, SCr was measured at least once every 2 weeks. CLcr was calculated using the Cockcroft–Gault equation [21]. CDDP-induced nephrotoxicity was defined as an increase in SCr after CDDP-based chemotherapy of at least one grade higher than the previous measure, using the Common Terminology Criteria for Adverse Events (CTCAE ver. 4.0) for AKI. The AKI classification is defined as an increase of SCr levels over a baseline of 1.5–2.0 times (grade 1), > 2.0–3.0 times (grade 2), and > 3.0 times or ≥ 4.0 mg/dL (grade 3). Although there are two grading systems for the criteria of renal failure, the “AKI of renal and urinary disorders” category and the “creatinine increased” of the investigations category, we adopted the AKI, the evaluation criteria based on the baseline value of creatinine before chemotherapy for each patient; this was in line with our previous report [20].
Statistical analyses

Patient characteristics and incidence of nephrotoxicity were summarized using descriptive statistics or contingency tables, and were compared using Student’s t-test and the chi-square test.

Propensity score matching (PSM) was used to reduce bias and balance the characteristics between the 8 mEq and 20 mEq Mg supplementation groups. The propensity score was calculated considering sex, age, cancer stage IV, cardiac disease, diabetes mellitus, hypertension, dosage of CDDP, albumin level, potassium level, and first cycle of chemotherapy as co-variables of logistic regression model. Patients were matched for variables at a 1:1 ratio using a caliper width of 0.2 of the standard deviation from the propensity score logit.

Additionally, to assess independent risk factors for nephrotoxicity, we used multivariate logistic regression to control for the potentially confounding roles of age, sex, Mg dosage, cardiac disease, hypertension, and CDDP dosage. Inclusion of variables in the model was based on existing knowledge of risk factors for nephrotoxicity and the literature [18, 20, 22, 23].

A two-sided $P$ value of <0.05 was considered statistically significant. All statistical analyses were performed using JMP 14.3.0 (SAS Institute, Cary, NC, USA).

Results

Patient characterization

Of the 345 eligible patients, 272 patients matched by PSM were analyzed: 136 received 8 mEq of Mg supplementation and 136 received 20 mEq of Mg supplementation. The patients’ baseline characteristics, including sex; age; the frequencies of stage IV, cardiac disease, diabetes, and hypertension; albumin; potassium; and CDDP dose, are shown in Table 1. There were no significant differences in these characteristics between the two groups after PSM.

The baseline characteristics of all eligible patients before PSM are summarized in Table S1 of Online Resource 1. The details of the delivery of CDDP-based chemotherapy and diuretics are summarized in Table S2 of Online Resource 1. All patients received conventional high-volume hydration to prevent CDDP-induced nephrotoxicity.

| Characteristics | Before propensity score matching | After propensity score matching |
|-----------------|---------------------------------|--------------------------------|
|                 | 8 mEq $n=184$ | 20 mEq $n=161$ | $P$-value | 8 mEq $n=136$ | 20 mEq $n=136$ | $P$-value |
| Sex             |                |                |          |                |                |          |
| Male            | 142            | 123            | 0.899    | 107            | 101            | 0.475    |
| Female          | 42             | 38             | 23.6     | 29             | 35             | 23.7     |
| Age, years      |                |                |          |                |                |          |
| <63             | 85             | 88             | 0.131    | 64             | 68             | 0.716    |
| ≥63             | 99             | 73             | 45.3     | 72             | 68             | 50.0     |
| Stage IV        |                |                |          |                |                |          |
| Yes             | 91             | 89             | 55.3     | 70             | 62             | 0.396    |
| No              | 93             | 72             | 44.7     | 66             | 74             | 54.4     |
| Cardiac disease |                |                |          |                |                |          |
| Yes             | 17             | 12             | 7.5      | 12             | 12             | 8.8      |
| No              | 167            | 149            | 92.5     | 124            | 124            | 91.2     |
| Diabetes mellitus|               |                |          |                |                |          |
| Yes             | 19             | 17             | 10.6     | 14             | 14             | 10.3     |
| No              | 165            | 144            | 89.4     | 119            | 122            | 89.7     |
| Hypertension    |                |                |          |                |                |          |
| Yes             | 45             | 50             | 31.1     | 33             | 32             | 23.5     |
| No              | 139            | 111            | 68.9     | 103            | 104            | 76.5     |
| Albumin, g/dL   |                |                |          |                |                |          |
| ≤3.9            | 101            | 80             | 49.7     | 69             | 59             | 43.4     |
| >3.9            | 83             | 81             | 50.3     | 67             | 77             | 56.6     |
| K, mEq/L        |                |                |          |                |                |          |
| ≥4.3            | 72             | 63             | 39.1     | 47             | 51             | 37.5     |
| <4.3            | 112            | 98             | 60.9     | 89             | 85             | 62.5     |
| CDDP dose, mg/m²|                |                |          |                |                |          |
| ≥75             | 99             | 115            | 71.4     | >0.001         | 90             | 66.2     |
| <75             | 85             | 46             | 28.6     | 47             | 46             | 33.8     |
| Number of cycles|                |                |          |                |                |          |
| 1               | 23             | 25             | 15.5     | 14             | 17             | 12.5     |
| ≥2              | 161            | 136            | 84.5     | 122            | 119            | 87.5     |

Supportive Care in Cancer (2022) 30:3345–3351
Incidence and severity of nephrotoxicity

The incidences of nephrotoxicity (grade 1 or higher) were 18.4% and 20.6% in the 8 mEq and 20 mEq groups, respectively. The proportions of patients with a grade 2 or higher elevation in creatinine after CDDP-based chemotherapy were 2.9% and 3.7% in the 8 mEq group and 20 mEq groups, respectively. There was no significant difference in the severity of nephrotoxicity according to CTCAE grading between the two groups (\(P = 0.926\)) (Table 2).

Changes in SCr and CLcr in all subsequent cycles

Figure 1 shows that there were no significant differences in the rate of change of SCr levels ([maximum SCr − baseline SCr] × 100/baseline SCr) and CLcr ([maximum CLcr − baseline CLcr] × 100/baseline CLcr) between the two Mg supplementation dose groups in all subsequent cycles (\(P = 0.988\) and \(P = 0.788\), respectively).

Risk factors for CDDP-induced nephrotoxicity

The results of the univariate and multivariate logistic regression analyses of the risk factors for nephrotoxicity are shown in Table 3. Only cardiac disease and an albumin level below 3.9 g/dL were identified as independent risk factors for CDDP-induced nephrotoxicity.

Discussion

Several studies have shown that intravenous Mg supplementation has preventive effects against CDDP-induced nephrotoxicity [13, 15–19, 24]. The dosage of Mg supplementation has varied widely in previous studies, ranging from 8 to 40 mEq [12, 13, 15–19, 24]. The NCCN has developed chemotherapy order templates for CDDP-based regimens, which consist of mannitol and 8 mEq Mg supplementation for the prevention of renal toxicity in cancer care, and this strategy has been adopted worldwide. Although some reports indicate the benefits of Mg supplementation at higher doses such as 20 mEq [18, 19] and 40 mEq [12], the optimal Mg supplementation dose for the prevention of CDDP-induced nephrotoxicity remains unknown because of a lack of comparative studies.

In the present study, we evaluated whether 20 mEq of Mg supplementation was more effective than 8 mEq in preventing CDDP-induced nephrotoxicity. To our knowledge, this is the first report comparing the dose of Mg supplementation for the prevention of CDDP-induced nephrotoxicity. There was no significant difference in the incidence of CDDP-induced nephrotoxicity between the 8 mEq and 20 mEq

---

**Table 2** Severity of nephrotoxicity

| Severity grade | 8 mEq | 20 mEq | \(P\)-value |
|----------------|-------|--------|-------------|
| n = 136        | n = 136 |
| Grade 0        | 111   | 108    | 0.926       |
| %              | 81.6  | 79.4   |             |
| Grade 1        | 21    | 23     |             |
| %              | 15.4  | 16.9   |             |
| Grade 2        | 3     | 3      |             |
| %              | 2.2   | 2.2    |             |
| Grade 3        | 1     | 2      |             |
| %              | 0.7   | 1.5    |             |

**Fig. 1** Comparison of the rate of change in SCr and CLcr between the 8 mEq and 20 mEq Mg supplementation groups in all subsequent cycles. Box-and-whisker plots for the relationship between 8 and 20 mEq dosages and the mean rate of change in the (a) serum creatinine level and (b) creatinine clearance during the subsequent cycles of CDDP-based chemotherapy. The difference between the two groups was analyzed using the unpaired Student t-test.

© Springer
groups. There was also no significant difference in the severity of nephrotoxicity, elevated SCr levels, and decreased estimated CrCl levels between the two groups. Cardiac disease and albumin level, but not Mg dosage, were identified as independent risk factors for CDDP-induced nephrotoxicity.

The serum Mg store is estimated to account for only 0.3% of the total Mg in the entire body [25]; therefore, it is unclear whether serum Mg levels reflect total body Mg conditions, including the condition of the kidney. Saito et al. [24] reported that the renal protective effect of Mg supplementation could be observed in the first course of chemotherapy, and the degree of serum Mg depletion remained constant in all subsequent cycles. These findings largely ruled out the prevention of serum Mg depletion as the mechanism underlying the protective effect of Mg against CDDP-induced nephrotoxicity.

To assess the risk factors for CDDP-induced nephrotoxicity, we performed multivariate analyses. We found that cardiac disease and an albumin level ≤ 3.9 g/dL were associated with an increased risk for CDDP-induced nephrotoxicity. In general, CDDP-induced nephrotoxicity has been associated with reduced levels of plasma proteins that bind to CDDP. Approximately 98% of CDDP binds to plasma proteins such as albumin [26], and nephrotoxicity is associated with peak plasma CDDP levels and/or the area under the plasma CDDP concentration–time curve for unbound CDDP [27, 28]. It is well known that hypoalbuminemia can lead to elevated free platinum concentrations and enhanced nephrotoxicity. Several studies have also indicated an association between CDDP-induced nephrotoxicity and comorbidities such as cardiac disease [22, 23]. In patients with cardiac disease, a reduction in renal perfusion caused by decreased cardiac output may affect the clearance of drugs eliminated by renal excretion. For example, renal clearance of vancomycin is reduced in patients with heart disorders [29]. Thus, decreased renal perfusion associated with cardiac disease can influence the clearance of CDDP. In addition, regular use of non-steroidal anti-inflammatory drugs (NSAIDs), male sex, and poor PS have been reported as risk factors for CDDP-induced nephrotoxicity [15, 18]; however, these factors were not identified to increase the risk of CDDP-induced nephrotoxicity in this study. This is possibly due to the fact that nearly 80% of the patients in our cohort were male, with a majority PS score of 0 or 1. Male sex and poor PS were also not identified as independent risk factors in our previous study [20]. Regular use of NSAIDs could not be considered in this study because of the small number of included patients using NSAIDs. In the previous reports [13, 15–19, 24], forced diuresis was used to prevent CDDP-induced nephrotoxicity, as in this study, while hydration was supplied either through conventional methods or short hydration. The interrelationship between forced diuresis and type of hydration in the prevention of CDDP-induced nephrotoxicity is unknown. The optimal dosage of Mg supplementation under short hydration conditions is a subject for further investigation.

Under conditions of forced diuresis and conventional high-volume hydration, 20 mEq Mg supplementation had no greater preventive effect on CDDP-induced nephrotoxicity than 8 mEq. In Japan, magnesium sulfate products at 20 mEq are conventionally used as electrolyte supplements. Since magnesium sulfate preparations are not expensive, if the cost is acceptable, the use of 20 mEq as a packaging unit might be useful in terms of risk management against preparation errors.

| Table 3 Risk factors for cisplatin-induced nephrotoxicity |
|----------------------------------------------------------|
| **Univariate**                                            |
| Mg (mEq)                                                 |
| 20 vs. 8                                                 |
| 1.151 (0.631–2.099)                                      |
| P-value                                                  |
| 0.760                                                    |
| Sex                                                      |
| Male vs. female                                          |
| 1.407 (0.662–2.990)                                      |
| Age (years)                                              |
| ≥ 63 vs. <63                                             |
| 0.974 (0.534–1.775)                                      |
| Cardiac disease                                          |
| Yes vs. no                                               |
| 2.782 (1.144–6.762)                                      |
| Hypertension                                             |
| Yes vs. no                                               |
| 1.682 (0.870–3.254)                                      |
| Albumin (g/dL)                                           |
| ≤ 3.9 vs. >3.9                                           |
| 1.962 (1.048–3.674)                                      |
| CDDP dose (mg)                                           |
| ≥ 75 vs. <75                                             |
| 1.771 (0.894–3.508)                                      |

**Multivariate**

| Mg (mEq)                                                 |
|----------------------------------------------------------|
| 20 vs. 8                                                 |
| 1.099 (0.590–2.065)                                      |
| P-value                                                  |
| 0.766                                                    |
| Sex                                                      |
| Male vs. female                                          |
| 1.459 (0.669–3.184)                                      |
| Age (years)                                              |
| ≥ 63 vs. <63                                             |
| 0.612 (0.307–1.222)                                      |
| Cardiac disease                                          |
| Yes vs. no                                               |
| 2.753 (1.039–7.290)                                      |
| Hypertension                                             |
| Yes vs. no                                               |
| 1.670 (0.798–3.496)                                      |
| Albumin (g/dL)                                           |
| ≤ 3.9 vs. >3.9                                           |
| 2.214 (1.133–4.325)                                      |
| CDDP dose (mg)                                           |
| ≥ 75 vs. <75                                             |
| 1.548 (0.766–3.130)                                      |

Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio
This study has some limitations. First, this was a retrospective observational study and not a randomized or prospective study. Second, individual quantifiable data of heart disease (e.g., cardiac output and ejection fraction) were not available; therefore, we defined heart disorders based only on the medical history of cardiac diseases such as angina or myocardial infarction. Third, since the data on serum Mg levels and the urine dipstick for hematuria/proteinuria were not available, these could not be considered in this study. Fourth, we were unable to examine other potential risk factors such as the regular use of NSAIDs. Fifth, the safety profile could not be determined in this pooled analysis because adverse event data were not available in the medical records for this analysis. Sixth, the sample size was relatively small. Finally, the inclusion of only cases with both forced diuresis and conventional high-volume hydration, as a method for preventing nephrotoxicity other than Mg supplementation, limits the generalizability of the study results.

In conclusion, we did not find an advantage of 20 mEq Mg supplementation over 8 mEq in terms of a preventive effect against CDDP-induced nephrotoxicity. The optimal dose of Mg supplementation for the prevention of CDDP-induced nephrotoxicity remains unknown, and further studies, such as randomized clinical trials, are warranted. Careful monitoring of Scr levels during CDDP-based chemotherapy is recommended for patients with heart disease and hypoalbuminemia.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00520-021-06790-w.

**Acknowledgements** We thank all of the participants of the study and their families.

**Author contribution** TH and TM conceived the study. TH performed statistical analyses. TM, TN, and TE provided technical support. TM, TH, FO, KT, SM, and CY contributed to the interpretation of data and assisted in the preparation of the manuscript. TH and TM prepared the initial draft of the manuscript. TM, TH, FO, KT, SM, CY, TN, and TE critically revised the manuscript. All authors reviewed and approved the final manuscript.

**Data availability** Data supporting the findings of this study are available from the corresponding author on reasonable request. However, restrictions apply to the availability of these data, which were used under a license for the current study and are, thus, not publicly available.

**Code availability** Not applicable.

**Declarations**

**Research involving human participants** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committees, and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

**Consent to participate and/or consent to publication** Not applicable; the requirement for informed consent was waived due to the retrospective nature of the study.

**Conflict of interest** The authors declare no competing interests.

**References**

1. Hartmann JT, Lipp HP (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4:889–901. https://doi.org/10.1517/14656566.4.6.889
2. Sastry J, Kellie SJ (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22:441–445. https://doi.org/10.1080/0888010590964381
3. Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368–379. https://doi.org/10.1016/s0272-6386(86)80112-3
4. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213:551–556
5. Pinzani V, Bressolle F, Haug JJ, Galtier M, Blayac JP, Balmès P (1994) Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35:1–9. https://doi.org/10.1007/BF00686277
6. Cornelson TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and oxaliplatin. Gynecol Oncol 50:147–158. https://doi.org/10.1006/gyno.1993.1184
7. Sobrero A, Guglielmi A, Aschele C, Rosso R (1990) Current strategies to reduce cisplatin toxicity. J Chemother 2:3–7. https://doi.org/10.1080/1120090x.1990.11738971
8. Finley RS, Fortner CL, Grove WR (1985) Cisplatin nephrotoxicity: a summary of preventative interventions. Drug Intell Clin Pharm 19:362–367. https://doi.org/10.1177/106002808501900505
9. Lajer H, Dauguaad G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 25:47–58. https://doi.org/10.1053/ctrv.1999.0097
10. Vickers AEM, Rose K, Fisher R, Saulnier M, Sahota P, Bentley P (2004) Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 32:577–590. https://doi.org/10.1080/10408440490508821
11. Alves SC, Tomasi CD, Constantino L, Giombelli V, Candal R, Brustot Mde L, Topanotti MF, Burdmann EA, Dal-Pizzol F, Fraga CM, Ritter C (2013) Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. Nephrol Dial Transplant 28:910–916. https://doi.org/10.1093/ndt/gfs268
12. Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarej-Wcislo K, Szczylik C (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44:2608–2614. https://doi.org/10.1016/j.ejca.2008.08.005
13. Willox JC, McAllister EJ, Sangster G, Kaye SB (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54:19–23. https://doi.org/10.1038/bjc.1986.147
14. Martin M, Díaz-Rubio E, Casado A, López Vega JM, Sastre J, Almenare J (1992) Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol 15:348–351. https://doi.org/10.1097/00000421-199208000-00016
15. Yoshida T, Niho S, Toda M, Goto K, Yoh K, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y (2014) Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study. Jpn J Clin Oncol 44:346–354. https://doi.org/10.1093/jjco/hyt004

16. Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, Yanase-Nakamura K, Tanaka H, Kato Y, Tabata M, Tanimoto M, Kiura K (2013) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama lung cancer study group Trial 1002. Jpn J Clin Oncol 43:1115–1123. https://doi.org/10.1093/jjco/hyt128

17. Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Waki H, Kanda S, Nokihara H, Yamamoto N, Sekine I, Tamura T (2013) Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 43:1105–1109. https://doi.org/10.1093/jjco/hyt122

18. Kidera Y, Kawai Y, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S-I, Tsuturani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K (2014) Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS ONE 9:e101902. https://doi.org/10.1371/journal.pone.0101902

19. Hase T, Miyazaki M, Ichikawa K, Yogo N, Ozawa N, Hatta T, Aso M, Sato M, Kondo M, Yamada K, Hasegawa Y (2020) Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study. Int J Clin Oncol 25:1928–1935. https://doi.org/10.1007/s10147-020-01755-1

20. Miyoshi T, Uoi M, Obara F, Tsumagarai K, Maesaki S, Yokota C (2021) Risk factors for cisplatin-induced nephrotoxicity: a multicenter retrospective study. Oncology 99:105–113. https://doi.org/10.1159/00051038421

21. Haim N, Oman SD, Galai N, Burde B, Nathan S, Catane R (1993) Estimation of creatinine clearance without 24-hour urine collection—a useful guide during cisplatin therapy. Acta Oncol 32:409–412. https://doi.org/10.3109/02841869309093618

22. Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC (2018) Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol 36:682–688. https://doi.org/10.1200/JCO.2017.75.7161

23. Mizuno T, Ishikawa K, Sato W, Koike T, Kushida M, Miyagawa Y, Yamada K, Hirata S, Imai E, Noda Y (2013) The risk factors of severe acute kidney injury induced by cisplatin. Oncology 85:364–369. https://doi.org/10.1159/000356587

24. Saito Y, Kobayashi M, Yamada T, Kasashi K, Homma R, Takeuchi S, Shimizu Y, Kinoshita I, Dosaka-Akita H, Iseki K (2017) Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Support Care Cancer 25:481–487. https://doi.org/10.1007/s00520-016-3426-5

25. Tong GM, Rude RK (2005) Magnesium deficiency in critical illness. J Intensive Care Med 20:3–17. https://doi.org/10.1177/088506604271539

26. Horiiuchi M, Inuyama Y, Kohno N, Mashino S, Fujii M (1982) Pharmacokinetics of cis-dichlorodiammineplatinum (II). Gan To Kagaku Ryoho 9:632–637

27. Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T, Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y (1996) Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 39:131–137. https://doi.org/10.1007/s002800050548

28. Nagai N, Ogata H (1997) Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 40:11–18. https://doi.org/10.1007/s002800050618

29. Teramachi H, Hatakeyama H, Matsushita R, Imai Y, Miyamoto KL, Tsuji A (2002) Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters. Biol Pharm Bull 25:1333–1338. https://doi.org/10.1248/bpb.25.1333

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.